Physician profile
Robert A Barnabei
NPI 1396708285
$3,143.82
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $476 · 2021: $1,420 · 2022: $858 · 2023: $139 · 2024: $30.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $579.17 | 2019-2023 | Lokelma |
| Novo Nordisk INC | $504.54 | 2019-2022 | |
| Abbvie INC. | $434.90 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.82 | 2020-2022 | |
| Lilly USA, LLC | $142.66 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.54 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $99.19 | 2020-2022 | |
| Astellas Pharma US INC | $93.43 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $88.49 | 2021-2024 | |
| Amarin Pharma, INC. | $84.58 | 2020-2022 | |
| Amgen INC. | $79.21 | 2020-2022 | |
| Eisai INC. | $72.64 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.30 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.92 | 2020-2021 | |
| Pfizer INC. | $55.95 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $49.35 | 2022 | |
| Glaxosmithkline, LLC. | $45.41 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $45.32 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $41.99 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $35.29 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $32.58 | 2020-2021 | |
| Exeltis, USA INC. | $26.79 | 2020-2021 | |
| Allergan, INC. | $24.91 | 2020 | |
| Avanir Pharmaceuticals, INC. | $20.43 | 2020 | |
| Medtronic, INC. | $17.77 | 2021 | |
| Esperion Therapeutics, INC. | $16.18 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $15.20 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.35 | 2020 | |
| Gilead Sciences, INC. | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Barnabei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.